文献速递眼底病与葡萄膜炎

全身用药与地图样萎缩的发病率及生长:CATT试验分析

SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
PubMed 文献 · Retina · 2021-01-01

该研究基于CATT试验,评估全身用药与地图样萎缩(GA)发病及生长的关联。1,011只无基线GA的研究眼多变量分析显示,所分析的全身药物均与GA发病无关;214只有纵向GA尺寸测量的研究眼中,钙通道阻滞剂与更高的GA生长率相关(0.40 vs. 0.30 mm/年,P=0.02)。

要点

  • 所分析的全身药物均与研究眼GA发病率无关(所有校正HR≤1.86,P≥0.18)。
  • 钙通道阻滞剂与研究眼GA生长率更高相关(0.40 vs. 0.30 mm/年,P=0.02)。

核心结论

  • 所分析的全身药物均未显示与GA发病率相关。
  • 钙通道阻滞剂与GA生长率更高相关。

研究设计与样本

  • CATT试验参与者,每例一只研究眼,随机接受贝伐珠单抗或雷珠单抗治疗。
  • 2年时退出临床试验治疗,约5年时检查。
  • 基线和第1、2、5年彩色眼底照片及荧光素血管造影由两名设盲评分者评估GA存在与大小。
  • 基线访谈全身用药情况,评估既往报道与AMD相关的全身药物。

主要发现

  • 1,011只无基线GA的研究眼多变量分析中,所分析的全身药物均与GA发病率无关(所有校正HR≤1.86,P≥0.18)。
  • 214只有纵向GA尺寸测量的研究眼多变量分析中,钙通道阻滞剂与更高的GA生长率相关(0.40 vs. 0.30 mm/年,P=0.02)。

关键数值与推荐

  • GA发病率分析:1,011只无基线GA的研究眼,所有校正HR≤1.86,P≥0.18。
  • GA生长分析:214只有纵向GA尺寸测量的研究眼,钙通道阻滞剂组GA生长率0.40 mm/年 vs. 0.30 mm/年,P=0.02。

临床怎么用

  • 所分析全身药物未见与GA发病相关,无需仅因GA风险调整这些药物。
  • 使用钙通道阻滞剂的患者可能GA生长更快,需关注随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine associations of systemic medications with the incidence and growth of geographic atrophy (GA) in participants of the comparison of age-related macular degeneration treatments trials. METHODS: Participants of comparison of age-related macular degeneration treatments trials with new untreated choroidal neovascularization in the study eye (one study eye per participant) were randomized to receive treatment with bevacizumab or ranibizumab. Participants were released from clinical trial treatment at 2 years and examined at approximately 5 years. Color fundus photographs and fluorescein angiograms taken at baseline, Years 1, 2, and 5 were assessed for the presence and size of GA by two masked graders. Participants were interviewed about systemic medication use at baseline. Systemic medications previously reported to be associated with age-related macular degeneration were evaluated for associations with GA incidence in study eye using univariable and multivariable Cox models and for association with the GA growth using linear mixed effects models. RESULTS: In multivariable analysis of 1,011 study eyes without baseline GA, systemic medications, including cholinesterase inhibitors, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids, and drugs targeting G protein-coupled receptors, were not associated with GA incidence in the study eye (all adjusted hazard ratios ≤1.86, P ≥ 0.18). In multivariable analysis of 214 study eyes with longitudinal GA size measurements, calcium channel blockers were associated with a higher GA growth rate (0.40 vs. 0.30 mm/year, P = 0.02). CONCLUSION: None of the systemic medications analyzed were associated with GA incidence. However, calcium channel blockers were associated with a higher growth rate of GA in the study eye.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Song D, Hua P, VanderBeek BL, et al. SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. Retina. 2021. PMID: 33332813. doi:10.1097/IAE.0000000000003075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。